Short-term surgical and long-term survival outcomes after laparoscopic distal gastrectomy with D2 lymphadenectomy for gastric cancer by Ke Chen et al.
Chen et al. BMC Gastroenterology 2014, 14:41
http://www.biomedcentral.com/1471-230X/14/41RESEARCH ARTICLE Open AccessShort-term surgical and long-term survival
outcomes after laparoscopic distal gastrectomy
with D2 lymphadenectomy for gastric cancer
Ke Chen, Yi-Ping Mou*, Xiao-Wu Xu, Jia-Qin Cai, Di Wu, Yu Pan and Ren-Chao ZhangAbstract
Background: Laparoscopic distal gastrectomy (LDG) for gastric cancer has gradually gained popularity. However,
the long-term oncological outcomes of LDG have rarely been reported. This study aimed to investigate the survival
outcomes of LDG, and evaluate the early surgical outcomes of laparoscopy-assisted distal gastrectomy (LADG) and
totally laparoscopic distal gastrectomy (TLDG).
Methods: Clinical outcomes of 240 consecutive patients with gastric cancer who underwent LDG at our institution
between October 2004 and April 2013 were analyzed. Early surgical outcomes of LADG and TLDG were compared
and operative experiences were evaluated.
Results: Of the 240 patients, 93 underwent LADG and 147 underwent TLDG. There were 109 T1, 36 T2, 31 T3, and
64 T4a lesions. The median follow-up period was 31.5 months (range: 4–106 months). Tumor recurrence was
observed in 40 patients and peritoneal recurrence was observed most commonly. The 5-year disease-free survival
(DFS) and overall survival (OS) rates according to tumor stage were 90.3% and 93.1% in stage I, 72.7% and 67.6% in
stage II, and 34.8% and 41.5% in stage III, respectively. No significant differences in early surgical outcomes were
noted such as operation time, blood loss and postoperative recovery between LADG and TLDG (P >0.05).
Conclusions: LDG for gastric cancer had acceptable long-term oncologic outcomes. The early surgical outcomes of
the two commonly used LDG methods were similar.
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Gastric cancer is one of the most common causes of
cancer-related death worldwide [1]. Although, adjuvant
chemotherapy improves the survival of these patients
[2,3], radical gastrectomy with regional lymph node dis-
section remains the only potentially curative treatment
available for gastric adenocarcinoma [4,5].
Since it was first reported in 1994 [6], laparoscopic
distal gastrectomy (LDG) for gastric cancer has under-
gone rapid development and gained popularity in the
past 20 years due to its well-known advantages, which
include a less painful course of recovery, earlier recovery,
better cosmesis, and improved short-term quality of life* Correspondence: mouyiping2002@163.com
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reproduction in any medium, provided the orover open gastrectomy [7-10]. Although the minimally
invasive effect of LDG is excellent, the therapeutic ef-
fects in adenocarcinoma still lack support from long-
term follow-up studies. The most common version of
LDG is laparoscopy-assisted distal gastrectomy (LADG)
and totally laparoscopic distal gastrectomy (TLDG). In
both of these techniques, perigastric lymphadenectomy is
performed under laparoscopy. However, the former re-
quires an epigastrium auxiliary incision for safe en bloc
extraction of the specimen, and to finish reconstruction of
the digestive tract. The latter is characterized by an intra-
corporeal anastomosis without auxiliary incision and it is
considered “incisionless”, with the exception of the trocar
wounds. Whether these two different anastomosis proce-
dures affect the short-term outcome of this type of surgery
remains controversial [11-13].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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oncologic outcomes of patients who underwent LDG, fo-
cusing on postoperative recurrence and survival rates. In
addition, the short-term surgical variables and outcomes
of LADG and TLDG were compared to evaluate the ad-
vantages and disadvantages of these procedures.
Methods
Patients
Between October 2004 and April 2013, 251 consecutive
patients who underwent LDG with D2 lymphadenectomy
for gastric cancer at Sir Run Run Shaw Hospital were
included in this study. The exclusion criteria included:
(1) invasion of adjacent structures; (2) palliative resection
or no R0 resection; (3) distant metastases (e.g. peritoneal
metastasis or peritoneal lavage cytology positive for car-
cinoma cells, hepatic metastasis); and (4) not confirmed
pathologically as adenocarcinoma.
Blood tests, chest X-rays, enhanced computed tomog-
raphy scans of the abdomen and pelvis, and gastric en-
doscopy were performed before surgery. This study
protocol was approved by our hospital’s ethics commit-
tee and informed consent was signed by each patient
prior to surgery.
Surgical procedure
The patient was placed in the supine position under
general anesthesia. The surgeon stood on the right side
of the patient. One assistant stood on the right side of
the patient and held the laparoscope, and another stood
on the left side of the patient. Carbon dioxide pneumo-
peritoneum was instituted through a Veress needle and
set at 15 mmHg. One initial 10-mm trocar was inserted
for laparoscopy below the umbilicus and another four
trocars (one of 12 mm, three of 5 mm) were inserted
into the left upper flank, left flank, right upper flank,
and right flank quadrants, respectively; a total of five
trocars were inserted, and arranged in a V-shape
[14,15]. D2 lymphadenectomy was performed accord-
ing to the Japanese gastric cancer guidelines which in-
cluded No. 7, 8, 9, 10, 11p, 11d, and 12a, and 14v in
addition to D1 dissection. Anastomosis methods in-
cluded Billroth I or Billroth II gastrojejunostomy. The
detailed lymphadenectomy and reconstruction pro-
cedure were described in our previously published
articles [16,17].
Data collection and follow-up evaluation
Demographics and perioperative data were retrospect-
ively collected from hospital records and analyzed. Clin-
ical and pathological staging were determined according
to the American Joint Committee on Cancer (7th edi-
tion), using the tumor-node-metastasis (TNM) classifica-
tion scheme. Adjuvant chemotherapy with 5-fluorouracil(5-FU)-based regimens (mostly 5-FU with cisplatin) was
recommended to all eligible patients, except those with
stage I cancers. Follow-up data were collected for at least
3 years, including alternating semiannual abdominopelvic
CT scans or ultrasound examinations. An endoscopic sur-
veillance was performed annually or earlier if the patient
had symptoms or there was any suspicion of recurrence.
Recurrence patterns included peritoneal, locoregional,
lymph node and hematogenous. Peritoneal recurrences in-
cluded peritoneal seedlings or Krukenberg’s tumors. Locor-
egional recurrences included tumors in adjacent organs,
remnant stomach or anastomoses. Hematogenous recur-
rences included tumors in other distant sites, such as liver,
lung, bone, and brain.Statistical analysis
Quantitative data were expressed as the means ± stand-
ard deviations (SD). The differences in the measurement
data were compared using the Student’s t test, and com-
parisons between groups were tested using the χ2 test or
the Fisher exact probability test. Disease-free survival
(DFS) and overall survival (OS) rates were calculated by
the Kaplan–Meier method using SPSS software, version
18.0 (SPSS Inc, Chicago, United States). DFS was defined
as the time from surgery to the time of recurrence of the
original gastric cancer or development of a second ma-
lignancy. OS was defined as the time from surgery to
date of death from any cause. P < 0.05 was considered
statistically significant.Results
Demographic and clinicopathologic characteristics
Among the 251 patients, 11 were excluded: five could
not undergo R0 resection (three with tumor invasion of
adjacent structures, two with conglomeration of lymph
nodes), three had distant metastases, and three did not
have adenocarcinoma (two neuroendocrine carcinomas,
one lymphoma). After excluding these 11 patients, 240
with curative intent were included in this study.
Demographic and clinicopathologic characteristics are
listed in Table 1. The mean age of the patients was
59.3 years (range, 30–81 years) and the male: female ra-
tio was 2.5:1 (171 males). Mean body mass index (BMI)
of the patients was 22.7 kg/m2 (range, 14.5–32.9 kg/m2).
Slightly more than a third (83/240; 34.6%) of the patients
had comorbidities, the most common being hypertension.
Of these 240 patients, 93 underwent LADG and 147
underwent TLDG. From the pathologic results, 45.4% of
patients had lesions that were staged as T1, 50.8% were
staged as N0, and 53.3% had stage I neoplasms. Approxi-
mately 55% of patients had advanced gastric cancer, de-
fined as tumor invasion into the proper muscular layer.
Table 1 Clinical characteristics and pathologic features
Variables Values
Gender (male/female) 171/69
Age (years) 59.3 ± 10.7
BMI (kg/m2) 22.7 ± 3.0








Tumor size (cm) 3.6 ± 2.0
Histology (differentiated/undifferentiated) 131/109
T stage (T1/T2/T3/T4a) 109/36/31/64
N stage (N0/N1/N2/N3) 122/57/36/25
TNM stage (I/II/III/IV) 128/45/67/0
Chen et al. BMC Gastroenterology 2014, 14:41 Page 3 of 7
http://www.biomedcentral.com/1471-230X/14/41Operative findings and postoperative clinical course
The operative findings and postoperative clinical course
data are shown in Table 2. The mean operation time was
231.1 min (range, 150–380 min), with a mean blood loss
of 136.3 mL (range, 20–420 mL). The mean number of re-
trieved lymph nodes per patient was 30.4 (range, 16–66).Table 2 Operative findings and postoperative clinical course
Variables Total (n = 240)
Reconstruction (Billroth I/Billroth II) 18/222
Operation time (min) 231.1 ± 48.1
Blood loss (mL) 136.3 ± 78.6
Number of retrieved lymph nodes 30.4 ± 8.6
Proximal resection margin (cm) 4.9 ± 1.5
Distal resection margin (cm) 5.0 ± 1.4
Time to first flatus (days) 3.7 ± 1.1
Time to starting liquid diet (days) 4.9 ± 1.8
Time to starting soft diet (days) 6.6 ± 2.4






Delayed gastric emptying 6
Pancreatic fistula 1
Ileus 1
Lymphorrhea 3The mean proximal and distal resection margins were
4.9 cm (range, 2–10 cm) and 5.0 cm (range, 2–11 cm), re-
spectively. The mean time to first flatus was 3.7 days
(range, 2–7 days). The mean times to starting liquid and
soft diets were 4.9 days (range, 3–22 days) and 6.6 days
(range, 4–24 days), respectively. Finally, the mean postop-
erative hospital stay was 9.8 days (range, 6–42 days). The
mean proximal margin distance of TLDG was longer than
that of LADG (5.1 ± 1.4 cm vs. 4.6 ± 1.2, P < 0.01). There
were no significant differences in other operative findings
and postoperative recovery between the LADG group and
the TLDG group (P > 0.05), although the mean operation
time, blood loss and time to first flatus were slightly lower
in the TLDG group than in the LADG group.
The rate of postoperative morbidity was 10.8% (26/
240 patients), and there was no perioperative mortality.
Morbidity included two cases of anastomotic leakage at
the gastrojejunostomy site (requiring surgical correc-
tion) and three cases of hemorrhage (two from the gas-
troduodenal artery and one from a branch of the splenic
artery), two of which required a second operation to stop
the bleeding. Other complications included abdominal ab-
scess (n = 5), pulmonary infection (n = 5), delayed gastric
emptying (n = 6), pancreatic fistula (n = 1), ileus (n = 1), and
lymphorrhea (n = 3). These complications were controlled
by conservative treatment. A comparison of morbidities in
the LADG group and TLDG group and type of complica-
tions did not show any differences, and the incidence ofLADG (n = 93) TLDG (n = 147) P value
11/82 7/140 0.075
238.0 ± 43.9 226.8 ± 50.2 0.080
146.0 ± 70.5 130.1 ± 83.0 0.126
29.5 ± 8.4 30.9 ± 8.8 0.228
4.6 ± 1.2 5.1 ± 1.4 0.002
4.9 ± 1.6 5.1 ± 1.4 0.393
3.9 ± 1.2 3.6 ± 1.1 0.085
4.9 ± 2.1 4.8 ± 1.6 0.794
6.7 ± 2.6 6.6 ± 2.2 0.958
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groups (P > 0.05).
Recurrence and survival
The mean and median follow-up was 39.7 and 31.5 months,
respectively (range: 4–106 months). Among the 240 pa-
tients, survival data were available for 232 patients. Eight
patients were lost to follow-up assessment, giving a follow-
up rate of 96.7% (232/240) for evaluation. Forty patients
developed tumor recurrence, 18 (45.0%) peritoneal recur-
rence, 11 (27.5%) distant or hematogenous recurrence, 7
(17.5%) lymphatic recurrence and 4 (10.0%) locoregional re-
currence. Of these patients, 33 died of gastric cancer recur-
rence, and 7 patients are still alive with disease at closure
date. Four other patients died due to causes other than gas-
tric cancer.
The 5-year DFS and OS in the entire cohort were 72.3%
and 75.9%, respectively. According to tumor stage, 5-year
DFS and OS were 90.3% and 93.1% in stage I, 72.7% and
67.6% in stage II, and 34.8% and 41.5% in stage III, re-
spectively (Figure 1). With regard to the depth of tumor,
5-year DFS was 90.6% in T1, 81.2% in T2, 67.6% in T3,
and 33.9% in T4a, and OS was 92.1%, 84.6%, 65.9%, and
40.7%, respectively (Figure 2).
Discussion
Due to its obvious advantages over traditional gastrectomy,
the number of patients undergoing LDG is rapidly increas-
ing, especially in eastern Asia, where gastric cancer is one
of the most common malignancies. The purpose of LDG in
gastric cancer patients is to meet oncologic demands and
not affect survival by minimizing operative insults.Figure 1 Kaplan-Meier survival curves according to different tumor stHowever, the use of LDG in gastric cancer has not yet
met with widespread acceptance because of the lack of
evidence regarding the oncological adequacy of laparo-
scopic procedures and the long-term results [18]. Opin-
ions still differ as to whether it can achieve the same effect
in D2 lymphadenectomy as open surgery and whether the
procedure is safe. It is well known that the adequacy of
radical resection should be evaluated by the extent of
lymph node dissection performed as well as the number
of retrieved lymph nodes (RLNs). Laparoscopic D2 lymph-
adenectomy is a complex operation and requires abundant
technical expertise due to the complicated vessels, numer-
ous anatomical layers and the complex lymph node me-
tastasis pathway around the stomach. Therefore, many
scholars still doubt whether LDG can achieve the same
radical effect as open surgery. However, some publications
have already described the number of RLNs in LDG with
D2 dissection as similar to that in open gastrectomy
[19,20]. In addition, some researchers have reported not
only a similar number of overall RLNs between laparos-
copy and laparotomy, but also a similar number of specific
lymph nodes, such as group 7, 8a, 9, 11p, 12a and 14v,
which were considered difficult in laparoscopic dissection
[21,22]. In our study, the mean number of RLNs per pa-
tient was 30.4 ± 8.6, which was enough for curability and
to determine lymph node metastasis. Park et al. [23] evalu-
ated the long-term results of 239 patients who underwent
LDG for the treatment of advanced gastric cancer (AGC).
They found that the major recurrence was distant metas-
tasis, whereas lymph node relapses were most frequent in
para-aortic or distant lymph node metastasis. Therefore,
they believe that the dissection of lymph nodes around theage. (A) Cumulative DFS. (B) Cumulative OS.
Figure 2 Kaplan-Meier survival curves according to depth of invasion (T). (A) Cumulative DFS. (B) Cumulative OS.
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ies and our data suggest that oncologically appropriate D2
lymphadenectomy can be carried out using laparoscopic
surgery.
Cancer recurrence and long-term survival rate are two
critical outcomes for evaluating surgical interventions in
oncological therapy. In this study, the 5-year DFS rate and
OS rate after LDG were 72.3% and 75.9%, respectively,
which was similar to that in previous studies [24]. In
addition, the survival results stratified according to staging
in the present study were comparable to historical data [25].
With regard to recurrence pattern, peritoneal recurrences
were more common in our study. However, some studies
demonstrated that the hematogenous pattern was most
common [26,27]. Hao et al. [28] compared cancer cells fol-
lowing exfoliating peritoneal washing between laparoscopic
and open gastrectomy for serosa-invaded AGC. The positive
rates of free cancer cells were 39.68% and 44.26% in the lap-
aroscopic and open groups, respectively, which was not sig-
nificantly different. Therefore, we believe that the difference
in recurrence pattern may due to the high proportion of
T4a tumors in our cohort. Port-site metastasis caused by in-
traoperative pneumoperitoneum is another controversial
issue. Shoup et al. [29] reported the long-term survival out-
comes of 449 gastric cancer cases who received diagnostic
laparoscopy, and only three cases developed port-site metas-
tasis. They concluded that port-site implantation after lapar-
oscopy was uncommon, and was not different from open
incision site recurrence. This type of metastases was not re-
ported in our study, similar to most other studies, thus we
believe that pneumoperitoneum does not contribute to a
higher risk of port-site metastasis.Several previous studies [11,12,30,31] reported some ad-
vantages of TLDG over LADG, such as reduced blood loss
and faster recovery. However, in our study, we could not
confirm the superiority of TLDG in postoperative recov-
ery. Because LADG is performed using a minilaparotomy
in the upper abdomen, it requires a longer incision than
TLDG. Therefore, some researchers argued that LADG
may be associated with greater analgesic use and more
pain than TLDG. However, Kim et al. [13] and our data
demonstrated that the small incision used for LADG does
not appear to be associated with more pain, a greater in-
flammatory response, or delayed recovery. In addition, the
proximal margin in LADG was shorter than that in TLDG
in our study. These results may be related to the nature of
LADG as it is difficult to pull the proximal stomach using
a narrow incision, which may influence the distance of the
proximal margin. It is noteworthy that our data do not re-
flect the effect of TLDG in patients with a high BMI. Some
researchers [32] reported that the frequency of painkiller
usage was higher in obese patients who underwent LADG.
This means that TLDG may be more favorable than
LADG in obese patients. In our practice, however, we
found that TLDG does have some advantages during in-
traoperative manipulation. First, TLDG is an in situ oper-
ation that avoids excessive pulling on the internal organs.
When conducting LADG, the gastric stump should be
pulled out of the body. This pulling places tremendous
stress on the gastric stump and may even lead to tearing
of the spleen envelope, causing bleeding. Also, the short
gastric blood vessels must be divided, especially in patients
with tumors in a high location. Conversely, intracorporeal
anastomosis could reduce stress on the gastric stump and
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more suitable for a “no touch tumor” operation. When
conducting LADG, the operator is limited to working
through a small incision, which leads to inevitable squeez-
ing of the tumor. There is a higher possibility that the
tumor will come into direct contact with the incision.
When conducting TLDG, the surgeon can achieve a “zero
extrusion”. Finally, in overweight patients, the auxiliary in-
cision of LADG may need to be extended to 8–10 cm.
However, when conducting TLDG, the surgeon can simply
expand the incision for the 10-mm trocar below the um-
bilicus to a 3–4 cm semicircle incision around the navel to
enable the sample to be removed as the hypogastrium wall
has more ductility.
Conclusions
The current study demonstrated that LDG accompanied
by D2 lymphadenectomy for gastric cancer provided an
acceptable prognosis and the number of retrieved lymph
nodes was considered to be oncologically acceptable. Both
LADG and TLDG can be performed safely and their
short-term surgical outcomes were similar. However, the
results mentioned above require verification by strictly de-
signed, large-sample, multicenter, prospective randomized
studies.
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